Category Archives: Psychedelics

Miami, Florida--(Newsfile Corp. - September 15, 2022) - HealingMaps, an informative and trusted psychedelic therapy search site announced today the close of $1 Million USD in seed round funding from eight investors. The round was led by Phyto Partners along with Ambria Capital. As part of the investment, Cody Shandraw, Managing Partner of Ambria Capital and Phyto Partners will take on the role as Board Chairman for HealingMaps.

"With its innovative UX, HealingMaps makes it easy for patients to search for services by location and medical specialty, then schedule appointments with just a few clicks," said Shandraw. "That ease-of-use combined with engaging content will be an important driver for the growth of this blossoming new healthcare field. I'm excited about the impact Healing Maps will have on the industry as a whole and I can't wait to see what the future holds."

Larry Schnurmacher, Managing Partner at Phyto sees the potential for HealingMaps to become a force in the emerging brain health megatrend. "Our investment into HealingMaps fits our strategy and thesis that people are increasingly focusing on their mind health as much as they focus on their physical health. HealingMaps provides information, education and resources for healthcare professionals and people seeking alternative mental wellness solutions. As the brain health megatrend takes hold, HealingMaps will be THE go-to website for PaaM (psychedelics as a medicine) and neuro-wellness."

"I don't think we could ask for two better partners to help lead HealingMaps into its next phase of growth," said Cory Jones, CEO of HealingMaps. "Mental health is experiencing a seismic shift right now, backed by an abundance of clinical research that shows the powerful impact of psychedelic compounds. With more and more psychedelic-assisted therapy retreats and clinics opening around the globe, patients need to know which ones they can trust, and which ones offer the right services. That's the value that HealingMaps provides, connecting people with cutting-edge resources so they can confidently decide which clinic and treatment is right for them."

Story continues

About HealingMaps Inc

HealingMaps was created as a source for individuals looking for accurate and honest information about psychedelic-assisted therapy and how to find qualified providers in their area. Inspired by the ground-breaking research and expanding access to these alternative treatments, HealingMaps is on a journey to become the world's most informative and trusted psychedelic-therapy search site. AND to reduce the friction between education & the path to an individual's healing - helping those that probably never knew that therapies would be available to them so close to home.

For more information, please contact:

Mark Goldhar, CFOTel: 902 478 7090Email: mark@healingmaps.comWebsite: https://healingmaps.com/

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/137171

See more here:

HealingMaps Announces $1 Million in Seed Funding to Power Growth in Psychedelic Therapy Industry - Yahoo Finance

A few days ago, Nav released his new album Demons Protected By Angels, which included features from Babyface Ray, Bryson Tiller, Don Toliver, Future, Lil Baby, and more. In a quick talk with HipHopDX, he revealed the moment he realized hed made it as a rapper which happened to be while he was on some psychedelics.

When I took mushrooms, I looked at myself from a third person perspective, he said, and I was like, Yo I f*ck with you dude. Dude really do this sh*t. Dude really take care of his mom, his family, everybody else. Boys is straight. What? Im real! Sounds like he had a good trip.

Nav also revealed in a different interview recently that he and Drake collaborated on a song that didnt make the cut for Demons Protected By Angels. We did a song. I feel we couldve done a better song and the timeframe was just not good, it didnt work out, he said. He added, Hes such a big artist that I didnt want to put the song on the album and have it take away from anything else on the album. You know, take away life from all the other moments.

Read more:

Nav Talks The Moment He Realized He Made It; It Involves Psychedelics - UPROXX

Objective: The authors provide an evidenced-based summary of the literature on the clinical application of psychedelic drugs in psychiatric disorders.

Methods: Searches of PubMed and PsycINFO via Ovid were conducted for articles in English, in peer-reviewed journals, reporting on "psilocybin," "lysergic acid diethylamide," "LSD," "ayahuasca," "3,4-methylenedioxymethamphetamine," and "MDMA," in human subjects, published between 2007 and July 1, 2019. A total of 1,603 articles were identified and screened. Articles that did not contain the terms "clinical trial," "therapy," or "imaging" in the title or abstract were filtered out. The 161 remaining articles were reviewed by two or more authors. The authors identified 14 articles reporting on well-designed clinical trials investigating the efficacy of lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and ayahuasca for the treatment of mood and anxiety disorders, trauma and stress-related disorders, and substance-related and addictive disorders as well as in end-of-life care.

Results: The most significant database exists for MDMA and psilocybin, which have been designated by the U.S. Food and Drug Administration (FDA) as "breakthrough therapies" for posttraumatic stress disorder (PTSD) and treatment-resistant depression, respectively. The research on LSD and ayahuasca is observational, but available evidence suggests that these agents may have therapeutic effects in specific psychiatric disorders.

Conclusions: Randomized clinical trials support the efficacy of MDMA in the treatment of PTSD and psilocybin in the treatment of depression and cancer-related anxiety. The research to support the use of LSD and ayahuasca in the treatment of psychiatric disorders is preliminary, although promising. Overall, the database is insufficient for FDA approval of any psychedelic compound for routine clinical use in psychiatric disorders at this time, but continued research on the efficacy of psychedelics for the treatment of psychiatric disorders is warranted.

Keywords: Ayahuasca; Drug-Psychotherapy Combination; Lysergic Acid Diethylamide; MDMA; Psilocybin; Psychedelics.

Original post:

Psychedelics and Psychedelic-Assisted Psychotherapy

You wont need any mind-altering substances for this psychedelic trip. A 12,000-square-foot experience called Psychedelics: The Experiential Exhibition is coming to Toronto at the end of this month and tickets are now on sale.

The event is described as Canadas first immersive art show exploring the past, present and future of psychedelics.

The exhibition dives into societys complex and often controversial relationship with psychedelics. It will provide a unique edutainment experience, combining audio and visual elements into an informative and fascinating display.

Visitors can roam three floors featuring spectacular original works from a diverse lineup of more than 22 internationally-acclaimed artists, says the description.

Recent PostsCanadas biggest vintage clothing sale is coming to Toronto this monthHalloween Haunt returns with new spooky maze & Day of the Dead festival

Every space will be dedicated to a different psychedelic substance and its historical and traditional uses.

Some of the highlights include an immersive peyote installation, a recreation of a 1960s Bay Area Acid Test, original images, and a fantastical video projection that explores the history and renewed popularity of psilocybin.

The grand finale is a 9-minute ayahuasca ceremony channelled via a shamanic totem in the second-floor ballroom, which is an audiovisual installation featuring lighting, sound, lasers, and projection mapping of a fully activated light sculpture.

My goal with the show is to, firstand foremost, provide guests with an entertaining and eye-opening experience, says the exhibitions producer James Drayton.

The testimonials are undeniable: patients with serious mental health conditions like PTSD, depression, anxiety or addiction are trying psychedelic therapies when nothing else has worked and reporting life-altering benefits,

My hope is that it also encourages learning, dialogue, and ultimately, destigmatization.

Sadly, it doesnt seem like there will be any magic mushrooms for sale on your way out, but the experience alone will definitely expand your mind.

Where: Lithuanian House, 1573 Bloor Street WestWhen: Wednesday to Sunday starting on September 30, 2022Cost: $30 per adult

Regional Editor, East Coast Lilly is a born and bred Toronto girl with a deep love for uplifting local stories. She has over 4 years of experience as an editor and has done some wildly unusual things to chase down a good story, like stake out Kyle Lowrys house and interview a professional candy taster. She also has a Husky named Freddy and an obsession with true crime.

Read more:

Toronto is getting a trippy psychedelics immersive exhibition this month - Curiocity

ByJulie Scharper

Psilocybinthe substance that puts the magic in magic mushroomscan help people emerge from depression, spur others to quit smoking, and even allow those facing terminal cancer to make peace with death.

The Food and Drug Administration and the Drug Enforcement Administration classified psilocybin as a "breakthrough therapy" for depression in 2018, a move many see as paving the way for the eventual approval of the drug as a treatment for mental health conditions. Patients are already clamoring for the treatment, which for many brings dramatic results in just a few sessions. The impending challenge? Training psychiatrists and other clinicians to administer psychedelics, which are significantly different from other classes of drugs prescribed for mental health.

A new $900,000 grant from the psychedelics-focused Heffter Research Institute will allow researchers from Johns Hopkins, Yale University, and New York University to build out a postdoctoral fellowship and gold-standard training program in psychedelic therapy. While some organizations have certification programs in psychedelics, they are often based on anecdotal observations, not hard data. "What is missing is an evidence-based approach," says Natalie Gukasyan, a Johns Hopkins assistant professor of psychiatry. Gukasyan, who is also medical director for the Johns Hopkins Center for Psychedelic & Consciousness Research, is leading Hopkins' efforts on the project.

Humans have been experimenting with psychedelics for millennia, but the substances first caught the attention of scientists in the 1950s when American banker R. Gordon Wasson wrote in Life magazine about his experiences taking hallucinogenic mushrooms with an Indigenous Mexican healer named Mara Sabina. More than 1,000 studies on psychedelics were launched between the mid-1950s and the early 1970s, but the drugs' association with hippies and Harvard-psychologist-turned-counter-culture-icon Timothy Leary led to fear and condemnation. In 1970, President Richard Nixon signed the Comprehensive Drug Abuse Prevention and Control Act, which outlawed psilocybin, LSD, and other psychedelics and effectively ended research on the drugs for more than two decades.

In 1993, David Nichols, at the time a psychopharmacology professor at Purdue University, formed the Heffter Research Institute to support plans to reinitiate studies of psychedelics. And in 2000, Roland Griffiths, a Hopkins psychiatry and neuroscience professor received FDA approval to begin studying psilocybin at Hopkins. Over the decades that followed, Griffiths has created protocols for using the hallucinogenic drug in clinical settings and led dozens of studies showing the safety and efficacy of psilocybin. The Center for Psychedelic & Consciousness Research opened at Hopkins in 2019 with Griffiths at the helm. More than 40 researchers now work at the center on studies looking at the effects of psilocybin on anorexia, smoking, major depressive disease, Alzheimer's disease, and other conditions.

The Heffter grant will enable psychedelics experts to put together a one-to-two-year postdoctoral fellowship program for psychiatrists interested in using psilocybin and other psychedelics in their practice. Fellows will learn about screening and preparing patients for psychedelic therapy, dosing, creating the right setting and mindset for the treatment, and providing psychotherapy to those undergoing treatment with psychedelics. Additionally, researchers will put together an evidence-based curriculum that will encompass the latest research on psychedelic therapies, Gukasyan says. Each university will receive $300,000 over the next two years to fund the creation of the program.

Gukasyan is "cautiously optimistic" that the Food and Drug Administration and the Drug Enforcement Administration will approve psilocybin for clinical use in the next five years or so, but there is no guarantee. The program will also train psychiatrists in other clinical interventions involving unusual states of consciousness, including Holotropic Breathwork, a breathing technique that puts participants in an altered state of mind.

Assuming the federal government clears the way for psilocybin to be used by clinicians, the materials crafted by the teams from three universities will provide a guidepost for creating other fellowships and training programs, Gukasyan says. "There is a lot of interest in psychedelic therapy because not only is it effective quickly, but it is highly effective," she says. "People are excited about these early results. The best we can hope for is that [clinicians] will be able to have this tool in their toolbox."

Read more here:

Preparing for a new era of psychedelic treatment - The Hub at Johns Hopkins

An upcoming webinar this month is aiming to demystify the complexities associated with the expanding clinical psychedelic industry.

On Wednesday, Xtalks announced that it would be hosting an upcoming online event entitled Psychedelic Research: Demystifying Complex Operations.

The educational webinar provider says the recent resurgence of interest in psychedelics inherently poses new challenges. Conducting responsible science and executing efficient clinical trials with previously researched psychoactive molecules in a modern-day regulatory environment are examples.

Read more:Field Trip facilitates beneficial psychedelic-assisted therapy for cancer patient

Read more:Filament administers psilocybin to 14 participants in Health Canada sanctioned clinical trial

For the upcoming free webinar on September 27, those in attendance will be educated by a panel of psychedelic operational experts from Xtalks partnerWorldwide Clinical Trials on properly navigating the challenging considerations required for undertaking clinical trials.

Xtalks says that attendees will also be taught how to select appropriate participants for clinical research, navigate current regulatory frameworks and acquire mandatory licenses.

For sponsors, investigators and regulators, psychedelics pose new clinical trial considerations. Dosing patients with these investigational products requires careful selection of both the clinical site, supportive therapists, efficacy raters and the patient themselves. Trust and support are paramount in this unique research partnership.

Xtalks specializes in providing informative webinars regarding medical devices, food and global life sciences. The organization says that it helps keep professionals updated on industry trends, regulations and developments.

Its partner for the upcoming webinar, Worldwide Clinical Trials, is a contract research organization (CRO) established in 1986 that specializes in neuroscience, oncology, general medicine and rare diseases.

We are clinicians, scientists, researchers, and tech wizards who facilitate the development of life-changing medicines.

Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Go here to see the original:

Xtalks to host upcoming webinar on psychedelic know-how - Mugglehead

Take a trip to Psychedelics: The Experiential Exhibition,the first immersive art show in Canada to explore the past, present, and future of psychedelics.

Delving into societys complex and controversial relationship with psychedelics, the exhibition utilizes a unique audiovisual edutainment experience.

Set to open on September 30, the show will span three floors within Torontos Lithuanian House. It will feature a 12,000-square-foot collection of curated artifacts and original installations by more than 22 artists.

Were seeing significant change in the way psychedelic substances are used and perceived, said James Drayton, producer of Psychedelics: The Experiential Exhibition.

My goal with the show is to, first and foremost, provide guests with an entertaining and eye-opening experience. My hope is that it also encourages learning, dialogue, and ultimately, destigmatization.

Bioworkz

Visitors will be guided through a series of curated spaces, each devoted to a different psychedelic substance and its historical or traditional uses.

Discover the psychoactive brew consumed in the Eleusinian Mysteries of Ancient Greece, and open your mind to the role of ayahuasca in Indigenous religious ceremonies in South America.

Take a trip through the Acid Tests and experimentation of the psychedelic 60s and explore LSDs current role as a promising therapy for intractable mental health conditions.

Highlights of the exhibition include an immersive peyote installation with massive hypnotic murals by Clandestinos, and a fantastical video triptych by Alex McLeod, which will be projected into a space exploring the history and renewed popularity of psilocybin.

The show will also feature a recreation of a 1960s Bay Area Acid Test, with mesmerizing liquid light visuals by Brotherhood of Light and Liquid Light Lab, former collaborators of the Allman Brothers and Grateful Dead.

The grand finale will be a fully immersive audiovisual installation by director and designer GMUNK.

Psychedelics: The Experiential Exhibition

Visitors are guided through a nine-minute ayahuasca ceremony thats channeled via a shamanic totem. Featuring lights, sounds, lasers, and projection mapping of a fully activated light sculpture, producers note its best experienced rather than described.

Until recently, the lively culture of psychedelic research and experimentation was forced underground, a release for the show reads.

Psychedelics: The Experiential Exhibition celebrates its recent renaissance while contemplating its future potential. Prepare to have your mind expanded.

When:Wednesdays through Sundays from September 30 to October 30

Where:Lithuanian House, 1573 Bloor Street West

Tickets: Available online | Starting at $30

Go here to see the original:

An immersive psychedelic exhibition is opening in Toronto this month | Listed - Daily Hive

Journalist Michael Pollan is the author of How to Change Your Mind. This is a fascinating book on the history of psychedelic drugs. The book follows the rise, fall and recent return of psychedelic research while examining the changing of their public and professional perception.

Recently, Netflix has also released a documentary series based on Pollans book that includes testimonials from people who have actually undergone the monitored experiment and talk about the various psychedelic benefits, that have changed their lives for the better.

If you were to take a walk down the streets, wouldnt you like to see more happy faces around you? People being calm, minding their own business, no frowns, no one having a panic attack right next to you in the bus Wouldnt that be nice? Most of you would say Of course, but that would happen in an ideal world and we dont live in one.

Some psychiatrists, neuro psychiatrists and psychologists, have studied the effects of psychedelics and their benefits when administered in a controlled environment, strictly for medical purposes. Although most psychedelics remain illegal under federal law, the FDA is weighing potential therapeutic uses for substances like psilocybin, LSD and MDMA (which is also known as Ecstasy).

To give you a broad kind of definition, the term psychedelic comes from the Greek psyche and delos so its translated to mind-manifesting. But not all psychedelics have the same action mechanism.

What if we could change our mindset and see these substances for the benefits that they can have on certain mental disorders? What if mental problems such as PTSD, alcoholism and depression could be cured by substances such as mescaline, psilocybin, MDMA or even LSD?

Lets find out more about these four substances and how they can be used in our advantage.

Probably many of you have heard scary things about LSD use. But the truth is that this is one of the least dangerous or addictive psychoactive drugs. However, this doesnt mean there is no risk in using it for personal entertainment. In fact, all the drugs in this list may have potential benefits but ONLY under monitored sessions where professionals can guide you and administer you the right dose.

More than 60 years ago, Albert Hofmann has first synthesized LSD from a fungus called ergot. LSD was first created with the intention to cure women with postnatal depression

Between 1950-1965, thousands of scientific articles about psychedelics were released, explaining their benefits from a medical point of view. However, like any other drug, LSD got into the hands of the wrong people and was distributed at parties, music festivals, and the results were catastrophic. Needless to say that the drug was soon banned from the market as it was considered an illicit drug.

Although professors from prestigious Universities tried to explain that microdoses of LSD can seriously alleviate symptoms of depression, anxiety, PTSD, and can help with problem solving issues, the drug has still remained illicit.

However, in the early 2000s, research slowly began to pick back up.

How astounding is that a substance called Psilocybin, found in a little mushroom can ameliorate the suffering of those who have cancer. Psilocybin can have a positive impact on their emotional and psychological distress which takes away from their quality of life.

A research was conducted on participants brains to actually see what happens at a neuro level after ingesting small doses of Psilocybin. Researchers have discovered that psychedelics work on the Default Mode Network the part houses the self and the assumptions about the self, the stories we tell ourselves

There are two kinds of science. The one that wants to look at only what can easily be measured and ignore everything else. And then theres the true science that proves the very frontiers of human knowledge, and that is where psychedelic research is right now.

Another small study on the therapeutic effects of using psychedelics to treat alcoholism found that just two doses of psilocybin magic mushrooms combined with psychotherapy led to an 83% decline in heavy drinking among the participants. After eight months, nearly half of those who received psilocybin had stopped drinking entirely.

The study published in JAMA Psychiatry has also talked about the benefits ofPsilocybin on a range of mental health problems, from depression, anxiety, PTSD and OCD.

MDMA (aka Ecstasy) is a synthetic drug that was first developed in 1912 and it was intended to control bleeding in hospital patients. Later, researchers have found that the drug also helped in enhancing communication in patient sessions and allowed them to achieve insights about their problems.

MDMA causes a flood of serotonin and oxytocin and that creates a feeling of openness, of loving connection to others. These feelings help reduce symptoms of depression and anxiety. Research also shows that in controlled doses paired with therapy, MDMA has positive effects on PTSD and on victims that were sexually abused.

Mescaline is a chemical substance that develops in two types of cactuses.It is said that it treats anxiety, depression and certain addictions such as alcoholism.

Mescaline was first used in the traditional ceremonies of Indigenous American cultures. The Natives have known of the plants hallucinatory and medicinal properties for thousands of years, and peyote still holds a sacred place in their culture. In fact, over 40 tribes in North America and Western Canada still use it in their sacred ceremonies.

Mescaline and peyote are now banned under United States drug laws, but such ceremonial use is exempted.

Mental health care is in crisis. We have rising rates of depression, suicide, anxiety, eating disorders, addictions, PTSD and OCD.

The studies comprised in Michael Pollans book How to Change Your Mind, suggest that psychedelics may have huge benefits on mental health if used properly and only under medical supervision.

As odd as it seems some of them can be effective for multiple forms of addiction, which is great news for those battling substance abuse.

However, keep in mind that this article is designed to inform. We do not provide medical advice. You should always consult a professional or a doctor before starting any type of treatment.

See original here:

Netflixs How to Change Your Mind Says Drugs Are the Answer Are They Right? - Goalcast

The 2022 NFL season is set to begin on Thursday night with the defending Super Bowl champion Los Angeles Rams hosting this years odds-on-favorite, the Buffalo Bills.

One thing that doesnt seem to change is Green Bay Packers quarterback Aaron Rodgers saying something wild and outlandish. The back-to-back NFL MVP has been at the center of controversy concerning his unvaccinated status, retirement threats and now his using psychedelics as a way of life.

During a recent interview on his good buddy Pat McAfees popular show, Rodgers made it known that his use of ayahuasca has given him a newfound love for life and the game of football.

Ive been enjoying football since I did ayahuasca. So the last few years have been great.

McAfee then wanted to know more.

Then well talk about ayahuasca, because Ive got a lot of questions. Your love of football though, since ayahuasca, why? New mindset, new vision on things, new look at things? Well, how come?

Rodgers quickly responded:

Yeah, mental health, bro. It starts out self-love, and when you increase that, then youre able to pass that on more easily. And listen, the locker room is where the chemistry takes place. Theres a lot of great things that happen on the practice field, and obviously in the game, and outside the facility is fun, and dinners and different things. But the locker room, thats the core of the connection.

Sounds like Rodgers is really comfortable where he is in life, both on and off the gridiron. He was just singing a different tune a few weeks ago as he complained about his receivers needing to step up and play better.

Rodgers Credits Back-To-Back MVPs From Ayahuasca Use

In early August Rodgers appeared on the Aubrey Marcus Podcast and said he believes its no coincidence that his back-to-back MVP seasons came after he began taking the plant-based psychedelic. He mentioned how his mental health improved and how it played a huge role in his changed mindset.

I dont think its a coincidence. I really dont. I dont really believe in coincidences at this point. Its the universe bringing things to happen when theyre supposed to happen.

Theres signs and synchronicities all around us at all times of were awake enough to see them and to take them in and listen to our intuition when its speaking to us or pounding us in the head saying, Hey, dummy, this is what youre supposed to be doing.

Rodgers proceeded to tell Marcus the decision to take ayahuasca stemmed from his previously delving into psychedelics. Hed go on to say one of the best days of life involved him consuming shrooms on the beach. He said he felt himself merge with the ocean following consumption.

Rodgers Looks For Third Consecutive MVP: But Without Top Target Davante Adams

Over the past two seasons, Rodgers passed for 8,414 yards, 85 touchdowns and just nine interceptions. But hell need to replace the 2,926 yards and 29 touchdowns that Davante Adams took with him to Las Vegas in the March blockbuster trade. While that will be nearly impossible, Rodgers will be forced to lean heavily on his running game and strong defense and maybe some psychedelics

Read More TSL Stories:

Cam Newtons Ex Takes Him To Court, Claims He Reneged On Deal To Pay $20K In Utilities | Them Bills Hits Different When NFL Checks Dry Up The Shadow League

Its Officially Savage Season | Tyreek Hill Becomes Second NFL Player To Slide In Jake Pauls Girlfriends DMs The Shadow League

Follow this link:

Yeah, Mental Health, Bro, It Starts With Self-Love | Aaron Rodgers Says His Use Of Psychedelics Has Increased His Passion For Life And The Game Of...

World Biz Magazine's Top 100 CEOs in Innovation list recognizes individuals who exhibit exceptional leadership and vision while making invaluable contributions to their industries.

VANCOUVER, BC, Sept. 7, 2022 /PRNewswire/ -Delic Holdings Corp ("Delic" or the "Company") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today celebrated Matt Stang, recently named Executive Chairman of Delic Corp, as one of World Biz Magazine's Top 100 CEOs in Innovation in 2022. Stang has been recognized as a champion of creativity who is committed to making a positive environmental and social impact through his work.

Matt Stang, CEO & Co-founder, Delic Corp (CNW Group/Delic Holdings Inc.)

Stang co-founded and grew Delic Corp into the nation's largest ketamine therapy provider. Under his leadership, the Company acquired Ketamine Wellness Centers (KWC), generated more than USD$1.5MM in total revenue in 2021 and more than quadrupled its net assets. Stang's ability to elevate the Company's ability to offer premium quality treatments to patients allowed him to transition from CEO to executive chairman in August 2022. In this position, Stang will continue to lead the Company in its mission to revolutionize healthcare.

"It is an honor to be recognized by World Biz Magazine as one of the foremost innovators in healthcare today. With the help of my talented team at Delic Corp, we continue to make safe, affordable treatments more accessible to patients across the country," Stang commented. "I firmly believe that our company's work is bettering the lives of people and communities every day. I am proud to be a part of this team and am truly excited to see what the future holds."

To learn more about Matt Stang's inclusion on World Biz Magazine's Top 100 CEOs in Innovation list, please visit http://www.worldbizmagazine.net.

About Delic Corp

Delicis a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The company owns and operates an umbrella of related businesses, including the largest chain of psychedelic wellness clinics in the country, Ketamine Wellness Centers; the only licensed entity by Health Canada to focus exclusively on research and development of psilocybin vaporization technology,Delic Labs; the premier psychedelic wellness event, Meet Delic; and trusted media and e-commerce platforms Reality SandwichandDelic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and better access to effective and affordable treatment options.

Story continues

Forward-Looking Information and Statements

This press release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic's control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved". The forward-looking information and forward-looking statements contained herein may include, but are not limited to: information regarding the timing or terms upon which the Transaction will be completed; potential benefits of the Transaction; anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics); the ability of Delic to successfully achieve business objectives, and expectations for other economic, business, and/or competitive factors.

By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. Such risks and other factors may include, but are not limited to: risks and uncertainties relating to the Transaction not closing as planned or at all or on terms and conditions set forth in the Merger Agreement; incorrect assessment of the value and potential benefits of the Transaction; direct and indirect material adverse effects from the COVID-19 pandemic; inability to obtain future financing on suitable terms; failure to obtain required regulatory and other approvals; risks inherent in the psychedelic treatment sector; changes in applicable laws and regulations; and failure to comply with applicable laws and regulations.

In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions. These assumptions include, but are not limited to: assumptions as to the time required to negotiate a definite agreement and complete matters related to the Transaction; the ability to consummate the Transaction; the ability of the parties to obtain, in a timely manner, the requisite regulatory, corporate and other third party approvals and the satisfaction of other conditions to the consummation of the Transaction on the proposed terms; the potential impact of the announcement or consummation of the Transaction on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time on the Transaction.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.

Delic Logo (CNW Group/Delic Holdings Inc.)

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/delic-executive-chairman-matt-stang-named-to-world-biz-magazines-top-100-ceos-in-innovation-301619157.html

SOURCE Delic Holdings Inc.

Link:

Delic Executive Chairman Matt Stang Named to World Biz Magazine's Top 100 CEOs in Innovation - Yahoo Finance